Select Publications
Book Chapters
2021, 'Cell-based methods for the identification of Myc-inhibitory small molecules', in The Myc Gene: Methods and Protocols, pp. 337 - 346, http://dx.doi.org/10.1007/978-1-0716-1476-1_19
,2014, 'Clinical relevance of multidrug-resistance-proteins (MRPs) for anticancer drug resistance and prognosis', in Efferth T; Bonavida B (ed.), Resistancce to Targeted Anti-Cancer Therapeutics, Springer Press., pp. 27 - 52
,2013, 'Cell-Based Methods for the Identification of MYC-Inhibitory Small Molecules', in Soucek L; Sodir NM (ed.), The Myc Gene, Humana Press Inc, pp. 255 - 264, http://dx.doi.org/10.1007/978-1-62703-429-6_18
,2013, 'Oncogene and Cancer - From Bench to Clinic', in Siregar YE; norris (ed.), Oncogene and Cancer - From Bench to Clinic, Inst za onkologiju i radiol, pp. 437 - 454, http://dx.doi.org/10.5772/54813
,2012, 'Small molecule drugs and targeted therapies for neuroblastoma', in Shimada H (ed.), Neuroblastoma - Present and Future, In Tech, Croatia, pp. 299 - 324, http://www.amazon.com/Neuroblastoma-Present-and-Future-ebook/dp/B00CBWQI92/ref=sr_1_1?ie=UTF8&qid=1366940364&sr=8-1&keywords=neuroblastoma+-+present+and+future#reader_B00CBWQI92
,2012, 'Targeting Multidrug Resistance in Neuroblastoma', in Hayat MA (ed.), Pediatric Cancer Volume 1 Diagnosis, Therapy and Prognosis: Neuroblastoma, Springer, New York, USA, pp. 115 - 123, http://dx.doi.org/10.1007/978-94-007-2418-1_11
,2012, 'The Myc Gene: Methods and Protocols: Myc inhibitory molecules', in Methods in Molecular Biology, Humana Press
,2000, 'Detection of Microscopic Residual Tumors in Bone Marrow', in Neuroblastoma, Elsevier Science BV, Amsterdam, pp. 333 - 340
,Journal articles
2024, 'Loss of stress sensor GADD45A promotes stem cell activity and ferroptosis resistance in LGR4/HOXA9-dependent AML.', Blood, http://dx.doi.org/10.1182/blood.2024024072
,2024, 'FDA-approved disulfiram as a novel treatment for aggressive leukemia', Journal of Molecular Medicine, 102, pp. 507 - 519, http://dx.doi.org/10.1007/s00109-023-02414-4
,2024, 'Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial', British Journal of Cancer, 130, pp. 788 - 797, http://dx.doi.org/10.1038/s41416-023-02525-2
,2023, 'Abstract B132: Addition of AMXT1501 (polyamine uptake inhibitor) plus DFMO (polyamine synthesis inhibitor) to standard-of-care chemotherapy/anti-GD2 antibody in the TH-MYCN mouse neuroblastoma model, enhances efficacy compared to addition of DFMO alone', Molecular Cancer Therapeutics, 22, pp. B132 - B132, http://dx.doi.org/10.1158/1535-7163.targ-23-b132
,2023, 'Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma', International Journal of Molecular Sciences, 24, http://dx.doi.org/10.3390/ijms242115571
,2023, 'Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia', Science translational medicine, 15, pp. eabm1262 - eabm1262, http://dx.doi.org/10.1126/scitranslmed.abm1262
,2023, 'Memory of stochastic single-cell apoptotic signaling promotes chemoresistance in neuroblastoma', Science Advances, 9, http://dx.doi.org/10.1126/sciadv.abp8314
,2022, 'Inflammatory response to retrotransposons drives tumor drug resistance that can be prevented by reverse transcriptase inhibitors', Proceedings of the National Academy of Sciences of the United States of America, 119, http://dx.doi.org/10.1073/pnas.2213146119
,2022, 'GSH facilitates the binding and inhibitory activity of novel multidrug resistance protein 1 (MRP1) modulators', FEBS Journal, 289, pp. 3854 - 3875, http://dx.doi.org/10.1111/febs.16374
,2022, 'The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression', Frontiers in Oncology, 12, pp. 863329, http://dx.doi.org/10.3389/fonc.2022.863329
,2022, 'In vitro and in vivo drug screens of tumor cells identify novel therapies for high-risk child cancer', EMBO Molecular Medicine, 14, pp. e14608, http://dx.doi.org/10.15252/emmm.202114608
,2022, 'Suppression of the ABCA1 Cholesterol Transporter Impairs the Growth and Migration of Epithelial Ovarian Cancer', Cancers, 14, pp. 1878, http://dx.doi.org/10.3390/cancers14081878
,2022, 'Systematic In Vitro Evaluation of a Library of Approved and Pharmacologically Active Compounds for the Identification of Novel Candidate Drugs for KMT2A-Rearranged Leukemia', Frontiers in Oncology, 11, pp. 779859, http://dx.doi.org/10.3389/fonc.2021.779859
,2022, 'Inhibition of mitochondrial translocase SLC25A5 and histone deacetylation is an effective combination therapy in neuroblastoma', International Journal of Cancer, 152, pp. 1399 - 1413, http://dx.doi.org/10.1002/ijc.34349
,2022, 'Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions', British Journal of Cancer, 127, pp. 908 - 915, http://dx.doi.org/10.1038/s41416-022-01806-6
,2021, 'Dual targeting of polyamine synthesis and uptake in diffuse intrinsic pontine gliomas', Nature Communications, 12, pp. 971, http://dx.doi.org/10.1038/s41467-021-20896-z
,2021, 'A Primer for Assessing the Pathology in Mouse Models of Neuroblastoma', Current Protocols, 1, pp. e310, http://dx.doi.org/10.1002/cpz1.310
,2021, 'Combination efficacy of ruxolitinib with standard-of-care drugs in CRLF2-rearranged Ph-like acute lymphoblastic leukemia', Leukemia, 35, pp. 3101 - 3112, http://dx.doi.org/10.1038/s41375-021-01248-8
,2021, 'Dual targeting of chromatin stability by the curaxin CBL0137 and histone deacetylase inhibitor panobinostat shows significant preclinical efficacy in neuroblastoma', Clinical Cancer Research, 27, pp. 4338 - 4352, http://dx.doi.org/10.1158/1078-0432.CCR-20-2357
,2021, 'Exploiting the reactive oxygen species imbalance in high-risk paediatric acute lymphoblastic leukaemia through auranofin', British Journal of Cancer, 125, pp. 55 - 64, http://dx.doi.org/10.1038/s41416-021-01332-x
,2021, 'Immunometabolism: A ‘Hot’ Switch for ‘Cold’ Pediatric Solid Tumors', Trends in Cancer, 7, pp. 751 - 777, http://dx.doi.org/10.1016/j.trecan.2021.05.002
,2021, 'Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG', Cell Reports, 35, pp. 108994, http://dx.doi.org/10.1016/j.celrep.2021.108994
,2021, 'A g316a polymorphism in the ornithine decarboxylase gene promoter modulates mycn‐driven childhood neuroblastoma', Cancers, 13, pp. 1807, http://dx.doi.org/10.3390/cancers13081807
,2021, 'A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma', Oncogene, 40, pp. 2367 - 2381, http://dx.doi.org/10.1038/s41388-021-01712-w
,2021, 'The RNA-helicase DDX21 upregulates CEP55 expression and promotes neuroblastoma', Molecular Oncology, 15, pp. 1162 - 1179, http://dx.doi.org/10.1002/1878-0261.12906
,2021, 'Targeted therapy of TERT-rearranged neuroblastoma with BET bromodomain inhibitor and proteasome inhibitor combination therapy', Clinical Cancer Research, 27, pp. 1438 - 1451, http://dx.doi.org/10.1158/1078-0432.CCR-20-3044
,2021, 'Whole-genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcoma', British Journal of Cancer, 126, pp. 482 - 491, http://dx.doi.org/10.1038/s41416-021-01538-z
,2020, 'Targeting TSLP-induced tyrosine kinase signaling pathways in CRLF2-Rearranged Ph-like ALL', Molecular Cancer Research, 18, pp. 1767 - 1776, http://dx.doi.org/10.1158/1541-7786.MCR-19-1098
,2020, 'Corrigendum to: “MAX to MYCN intracellular ratio drives the aggressive phenotype and clinical outcome of high risk neuroblastoma” [Biochim. Biophys. Acta, Gene Regul. Mech. 1861 (2018) 235–245] (BBA - Gene Regulatory Mechanisms (2018) 1861(3) (235–245), (S1874939917302894), (10.1016/j.bbagrm.2018.01.007))', Biochimica et Biophysica Acta - Gene Regulatory Mechanisms, 1863, http://dx.doi.org/10.1016/j.bbagrm.2020.194645
,2020, 'Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer', Nature Medicine, 26, pp. 1742 - 1753, http://dx.doi.org/10.1038/s41591-020-1072-4
,2020, 'ABCC4/MRP4 contributes to the aggressiveness of Myc-associated epithelial ovarian cancer', International Journal of Cancer, 147, pp. 2225 - 2238, http://dx.doi.org/10.1002/ijc.33005
,2020, 'Suppression of ABCE1-mediated mRNA translation limits N-MYC-driven cancer progression', Cancer Research, 80, pp. 3706 - 3718, http://dx.doi.org/10.1158/0008-5472.CAN-19-3914
,2020, 'Targeting RSPO3-LGR4 Signaling for Leukemia Stem Cell Eradication in Acute Myeloid Leukemia', Cancer Cell, 38, pp. 263 - 278.e6, http://dx.doi.org/10.1016/j.ccell.2020.05.014
,2020, 'OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis', Leukemia, 34, pp. 1828 - 1839, http://dx.doi.org/10.1038/s41375-019-0692-5
,2020, 'Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia', Leukemia, 34, pp. 1524 - 1539, http://dx.doi.org/10.1038/s41375-019-0683-6
,2020, 'Targeting metabolic activity in high-risk neuroblastoma through Monocarboxylate Transporter 1 (MCT1) inhibition', Oncogene, 39, pp. 3555 - 3570, http://dx.doi.org/10.1038/s41388-020-1235-2
,2020, 'CCI52 sensitizes tumors to 6-mercaptopurine and inhibits MYCN-amplified tumor growth', Biochemical Pharmacology, 172, pp. 113770, http://dx.doi.org/10.1016/j.bcp.2019.113770
,2020, 'Accelerating development of high-risk neuroblastoma patient-derived xenograft models for preclinical testing and personalised therapy', British Journal of Cancer, 122, pp. 680 - 691, http://dx.doi.org/10.1038/s41416-019-0682-4
,2019, 'JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma', Nature Communications, 10, pp. 3319, http://dx.doi.org/10.1038/s41467-019-11132-w
,2019, 'The long noncoding RNA lncNB1 promotes tumorigenesis by interacting with ribosomal protein RPL35', Nature Communications, 10, pp. 5026, http://dx.doi.org/10.1038/s41467-019-12971-3
,2019, 'Drugging MYCN oncogenic signaling through the MYCN-PA2G4 binding interface', Cancer Research, 79, pp. 5652 - 5667, http://dx.doi.org/10.1158/0008-5472.CAN-19-1112
,2019, 'MRP1 modulators synergize with buthionine sulfoximine to exploit collateral sensitivity and selectively kill MRP1-expressing cancer cells', Biochemical Pharmacology, 168, pp. 237 - 248, http://dx.doi.org/10.1016/j.bcp.2019.07.009
,